Eli Lilly

Johnson & Johnson

McKesson

Bristol-Myers

AbbVie

CoreSite Realty

Merck

Zoetis

Pfizer

Viatris

VanEck Vectors Pharmaceutical ETF

PPH tracks a market-cap-weighted index of 25 of the largest global pharmaceutical firms.

The VanEck Pharmaceutical ETF (PPH) was launched on 12/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

The VanEck Pharmaceutical ETF has shown strong performance but faces near-term downside risks, prompting a rating downgrade from buy to hold. PPH's valuation has increased significantly, with a high price-to-earnings ratio and concentrated portfolio, particularly in top holdings like LLY and NVO. Technical indicators suggest bearish momentum, with potential support in the mid-$80s, making it a favorable risk/reward buy on further pullback.

Pharma Stocks Losing Ground After A Remarkable Rally, Downgrading PPH

The healthcare sector hasn't been a bad performer, per se. Year-to-date, the S&P Health Care Select Sector Index is up 13.1%, but that lags the S&P 500 by 800 basis points, confirming investors have cause to be frustrated with blue-chip pharmaceuticals and biotechnology equities.

Healthcare ETFs Starting to Look Healthy

Vanguard Short-Term Bond ETF

Capital Group Dividend Value ETF

Dimensional Short-Duration Fixed Income ETF

WisdomTree India Earnings Fund

Franklin FTSE India ETF

SPDR Gold Trust

SPDR Gold MiniShares Trust

iShares Gold Trust

iShares MSCI India ETF

PIMCO Enhanced Short Maturity Active ETF

VanEck Merk Gold Trust

Global X U.S. Infrastructure Development ETF

Schwab US Dividend Equity ETF

iShares 20+ Year Treasury Bond ETF

Vanguard Long-Term Treasury ETF

BondBloxx USD High Yield Bond Consumer Non-Cyclicals Sector ETF

Consumer Staples Select Sector SPDR Fund

Blurring the lines between conference and festival, this year's Future Proof brought thousands of attendees to the summery shores of Huntington Beach in Los Angeles.

DoubleLine's Jeff Gundlach on the Fed, Gold and Private Credit

Broadly speaking, the healthcare sector remains a laggard relative to the broader market. As of Aug. 28, the S&P Select Sector Health Care Index was trailing the S&P 500 by 310 basis points on a year-to-date basis.

This Pharma ETF Could Be Ideal Healthcare Pick

First Trust Nasdaq Pharmaceuticals ETF 

iShares U.S. Pharmaceuticals ETF

Invesco Dynamic Pharmaceuticals ETF

SPDR S&P Pharmaceuticals ETF

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

Pharma ETFs in Focus Post Solid Q2 Earnings

Fidelity MSCI Consumer Staples ETF

Tema Obesity & Cardiometabolic ETF

iShares U.S. Aerospace & Defense ETF

iShares U.S. Healthcare ETF

iShares U.S. Consumer Goods ETF

Roundhill GLP-1 & Weight Loss ETF

Invesco Aerospace & Defense ETF

Global X Defense Tech ETF

Amplify Weight Loss Drug & Treatment ETF

Vanguard Consumer Staples ETF

Vanguard Utilities ETF

SPDR S&P Aerospace & Defense ETF

Utilities Select Sector SPDR Fund

Health Care Select Sector SPDR Fund

When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.

Disruptive Theme of the Week: Playing Defense

The Health Care sector bullish due to AI technology. VanEck Pharmaceutical ETF offers exposure to leading pharmaceutical companies. The defensive nature of the pharmaceutical sector makes it somewhat recession-proof, but high costs and regulatory risks are potential drawbacks.

PPH: A Strong Fund To Play Big Pharma

Amplify Global Cloud Technology ETF

Amplify Alternative Harvest ETF

Amplify US Alternative Harvest ETF

AdvisorShares Pure US Cannabis ETF

MUSQ Global Music Industry ETF

First Trust Cloud Computing ETF

VanEck Vectors Semiconductor ETF

iShares PHLX Semiconductor ETF

Digging into the first quarter's earnings season allows us to uncover the winning themes of the period as captured by ETFs.

Thematic ETF Winners of the Q1 2024 Earnings Season

A Look at Pharma ETFs Post Q1 Earnings

Horizon Kinetics Medical ETF

Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.

ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook

Weight-loss drugs, including Ozempic, are reshaping consumer habits. Additionally, they are providing some ballast to what's recently been a sluggish healthcare investment thesis.

Weight-Loss Drugs Boost Case for Pharma ETFs

VanEck Pharmaceutical ETF is a popular option for investors looking for exposure to leading pharmaceutical companies. The ETF has been in an uptrend since late last year and is currently trading at a level that presents a buying opportunity. The ETF's top holdings include Eli Lilly, Novo Nordisk, and Johnson & Johnson, with potential for future growth.

PPH: Buy The Pullback In This Big Pharma ETF For Long-Term Total Returns

Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.

JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus

iShares U.S. Healthcare Providers ETF

Janus Detr Strt Shs Obesity

People are interested in ETFs for weight loss because of Oprah's TV show “Shame, Blame, and the Weight Loss Revolution,” which was about weight loss drugs. A lot of people are upset that she's talking to patients and doctors about using prescription drugs to lose weight, but it's still causing a stir.

3 Weight-Loss ETFs to Profit From the Obesity Drug Boom

Global X Artificial Intelligence & Technology ETF

Pacer US Cash Cows 100 ETF

Top ETFs to buy offer a smart solution for those looking to diversify their portfolios without the hassle. In the investment realm, diversification remains a key aspect of a sound investment strategy, but achieving it may feel like a Herculean task.

The Top 3 ETFs to Buy in March 2024

Global X Longevity Thematic ETF 

Healthcare stocks started the year off very strongly as investors cheered the sector's advances. Among the sector's catalysts have been continued, strong enthusiasm for a new class of weight-loss drugs called GLP-1 and Nvidia's decision, disclosed earlier this month, to invest in a medical imaging company and a firm that uses artificial intelligence ( AI ) to speed up the drug discovery process.

The 3 Hottest Healthcare ETFs to Buy in 2024

Investors seeking momentum may have iShares VanEck Pharmaceutical ETF PPH on radar now. The fund recently hit a new 52-week high.

Pharma ETF (PPH) Hit a 52-Week High

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs After Q4 Earnings

Pharmaceuticals underperformed the S&P 500 in 2023 but have been outperforming the broader market in 2024. The PPH fund offers exposure to pharmaceutical stocks and has outperformed its peers in terms of performance and liquidity. The fund is undervalued compared to the projected earnings growth of its top holdings, making it a compelling pick for investors.

PPH: Ignore The Election Scare, Buy Pharma And Healthcare

Fidelity MSCI Health Care ETF

iShares Nasdaq Biotechnology ETF

Vanguard Health Care ETF

SPDR S&P Biotech ETF

The healthcare sector presents a unique investment opportunity in 2024 due to attractive valuation and uncorrelated/robust cashflow of healthcare. Biopharma companies have pricing power and ability to adjust drug prices in line with inflation, providing advantage in inflationary environment.

Healthcare In 2024: Navigating The Biopharma Bull Run

WisdomTree Japan Hedged SmallCap Equity Fund

Invesco S&P 500 Enhanced Value ETF

Financial Select Sector SPDR Fund

The start of 2024 has been weak for the global stock market after a blockbuster 2023. Still, a few corners of the stock market are outperforming, pushing ETFs to new 52-week highs.

5 ETF Zones Scaling New Highs at the Start of 2024

SPDR S&P 500 ETF Trust

After underperforming in 2023, the healthcare sector seems to be back on track at the start of the New Year. Healthcare generally outperforms during periods of low growth and high uncertainty.

Healthcare ETFs Start 2024 on a Positive Note

Despite Eli Lilly's monster 66.8% gain on the year because of weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.

Pharma Is Out of Favor. 5 Drug Stocks With Room to Grow.

The XBI has been climbing this month. On Tuesday it jumped 5.4% to close at $70.91.

News for VanEck Vectors Pharmaceutical ETF ETF (PPH)